Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

PURPOSE: To develop a genomic signature that predicts benefit from trastuzumab in human epidermal growth factor receptor 2–positive breast cancer. PATIENTS AND METHODS: DASL technology was used to quantify mRNA in samples from 1,282 patients enrolled onto the Combination Chemotherapy With or Without...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Perez, Edith A., Thompson, E. Aubrey, Ballman, Karla V., Anderson, S. Keith, Asmann, Yan W., Kalari, Krishna R., Eckel-Passow, Jeanette E., Dueck, Amylou C., Tenner, Kathleen S., Jen, Jin, Fan, Jian-Bing, Geiger, Xochiquetzal J., McCullough, Ann E., Chen, Beiyun, Jenkins, Robert B., Sledge, George W., Winer, Eric P., Gralow, Julie R., Reinholz, Monica M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4334774/
https://ncbi.nlm.nih.gov/pubmed/25605861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.6298
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados